Spots Global Cancer Trial Database for magrolimab
Every month we try and update this database with for magrolimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma | NCT05738161 | Advanced Urothe... | Magrolimab Cisplatin Gemcitabine | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | NCT05330429 | Metastatic Colo... | Magrolimab Bevacizumab Irinotecan Fluorouracil Leucovorin | 18 Years - | Gilead Sciences | |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | NCT05330429 | Metastatic Colo... | Magrolimab Bevacizumab Irinotecan Fluorouracil Leucovorin | 18 Years - | Gilead Sciences | |
| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | NCT05807126 | Anatomic Stage ... Castration-Resi... Stage IVB Prost... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Magrolimab Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Magrolimab in Patients With Solid Tumors | NCT04827576 | Solid Tumor | Magrolimab Docetaxel | 18 Years - | Gilead Sciences | |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | NCT02953509 | Non Hodgkin Lym... | Magrolimab Rituximab Gemcitabine Oxaliplatin | 18 Years - | Gilead Sciences | |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | NCT04751383 | High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection | 2 Years - 35 Years | National Cancer Institute (NCI) | |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | NCT04854499 | Head and Neck S... | Magrolimab Pembrolizumab Docetaxel 5-FU Cisplatin Carboplatin Zimberelimab | 18 Years - | Gilead Sciences | |
| Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | NCT04778397 | Acute Myeloid L... | Magrolimab Venetoclax Azacitidine Cytarabine Daunorubicin Idarubicin Steroidal Eye D... | 18 Years - | Gilead Sciences | |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer | NCT04958785 | Triple-Negative... | Magrolimab Nab-Paclitaxel Paclitaxel Sacituzumab Gov... | 18 Years - | Gilead Sciences | |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma | NCT06046482 | Head Neck Squamous Cell C... | Pembrolizumab Magrolimab cetuximab Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | NCT03248479 | Hematological M... | Magrolimab Azacitidine | 18 Years - | Gilead Sciences | |
| Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy | NCT03558139 | Ovarian Cancer | Magrolimab Avelumab | 18 Years - | Gilead Sciences | |
| Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy | NCT03558139 | Ovarian Cancer | Magrolimab Avelumab | 18 Years - | Gilead Sciences | |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | NCT05169944 | Brain Cancer Malignant Brain... Recurrent Brain... Progressive Mal... Brain Tumor, Pe... Brain Tumor Adu... | Magrolimab | 3 Years - | University of California, San Francisco | |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | NCT04313881 | Myelodysplastic... | Magrolimab Azacitidine Placebo | 18 Years - | Gilead Sciences | |
| Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | NCT05079230 | Acute Myeloid L... | Magrolimab Venetoclax Azacitidine Magrolimab Plac... | 18 Years - | Gilead Sciences | |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | NCT04313881 | Myelodysplastic... | Magrolimab Azacitidine Placebo | 18 Years - | Gilead Sciences | |
| Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | NCT04313881 | Myelodysplastic... | Magrolimab Azacitidine Placebo | 18 Years - | Gilead Sciences | |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | NCT04435691 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Azacitidine Magrolimab Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | NCT05169944 | Brain Cancer Malignant Brain... Recurrent Brain... Progressive Mal... Brain Tumor, Pe... Brain Tumor Adu... | Magrolimab | 3 Years - | University of California, San Francisco | |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | NCT04599634 | Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Chronic Lymphoc... B-Cell Lymphoma | Obinutuzumab Venetoclax Magrolimab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | NCT02953782 | Solid Tumor Colorectal Canc... | Magrolimab Cetuximab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
